Skip to main content

Nerlynx News

Puma Biotechnology Receives U.S. FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer

LOS ANGELES, Calif., Feb. 26, 2020 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug...

FDA Approves Nerlynx (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer

July 17, 2017 – The U.S. Food and Drug Administration today approved Nerlynx (neratinib) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer. For patients with this type...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Breast Cancer - Adjuvant

Nerlynx patient information at Drugs.com